Press Release Source: Viragen, Inc.
Viragen Announces That OVA(TM) System Results are Published in Leading U.S. Scientific Journal
Tuesday January 16, 9:06 am ET
PLANTATION, Fla., Jan. 16 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA; VRA.U; VRA.WS) and its collaborative partners in the field of avian transgenics, Roslin Institute and Oxford Biomedica Plc (LSE: OXB - News), today announced that the Proceedings of the National Academy of Sciences of the United States of America (PNAS), a leading scientific journal, has published an article profiling the OVA(TM) System's ability to express two therapeutic proteins in the whites of eggs of transgenic hens. The OVA(TM) System is being developed as a novel, large-scale biomanufacturing alternative capable of cost-effectively expressing many types of therapeutic proteins.
The article, entitled, "Oviduct-specific expression of two therapeutic proteins in transgenic hens," reports on the production of two protein drug candidates: a humanized monoclonal antibody being developed by Viragen for advanced malignant melanoma; and interferon beta-1a, which is currently marketed under two competing brand names for the treatment of Multiple Sclerosis (MS), as Avonex®* (Biogen Idec) and Rebif®** (Serono).
AI
